European Journal of Endocrinology · 2007 · 85 citations · 21 references
MedicineEndocrinologyClinical NutritionMetabolic PhysiologyMetabolic RegulationCardiometabolic Risk ReductionCardiovascular DiseaseEndocrine Metabolic DisordersMetabolic DiseaseMetabolic DisordersMetabolic SyndromeCardiometabolic DiseaseCardiovascular Risk MarkersMetabolic Syndrome DyslipidemiaMetabolic Syndrome EpidemiologyOutcome MeasuresPrevalence Estimation
OBJECTIVES: Many reports demonstrate improvements in cardiovascular risk factors during GH replacement (rhGH) in adult GH deficiency (GHD). However, it remains to be determined to what extent these changes translate into a reduction of increased cardiovascular morbidity and mortality. The aim of this study was to evaluate the effects of long-term rhGH replacement on the prevalence of the metabolic syndrome (MS). Design, settings, main outcome measures: The MS was scored by the National Cholesterol Education Program-Adult Treatment Panel III definition in 50 consecutive GHD patients (45 +/- 9 years of age), before and after 2 and 5 years of rhGH replacement, and the data of untreated patients were compared with the general population using data from a Dutch population-based study (n=1062, 44 +/- 8 years of age). RESULTS: Hypertriglyceridaemia (46.0 vs 18.5%, P<0.0001), hypertension (66.0 vs 35.5%, P<0.0001) and abdominal obesity (38.0 vs 23.4%, P=0.0178) were more prevalent in untreated patients when compared with controls, resulting in a higher prevalence of the MS in patients (38.0 vs 15.7%, P<0.0001). During rhGH replacement at a mean dose of 0.5 +/- 0.2 mg/day resulting in IGF-I concentrations in the normal age-adjusted reference range, mean high-density lipoprotein cholesterol level increased compared with baseline (P<0.001). However, the prevalence of (components of) the MS did not change after 2 or 5 years of treatment with rhGH. CONCLUSION: In this study, the prevalence of the MS in patients with GHD is increased compared with healthy controls, irrespective of rhGH replacement.
21
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Bo Isomaa, Peter Almgren, Björn Forsén et al. · Diabetes Care · 2001 · 4.8K citations
Medicine, Endocrinology, Diabetology +15
Banting lecture 1988. Role of insulin resistance in human disease
Gerald M. Reaven · Diabetes · 1988 · 3.8K citations
Medicine, Endocrinology, Physiology +11
Metabolic Syndrome and 10-Year Cardiovascular Disease Risk in the Hoorn Study
Cynthia J. Girman, Thomas Rhodes, Giel Nijpels et al. · Circulation · 2005 · 631 citations · Full text